Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1746]

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia

Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia ( Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France )

First all-oral treatment for relapsed and treatment-resistant multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

First all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

Experimental oral therapy for high-risk CLL shows promise

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Experimental oral therapy for high-risk CLL shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )

Idelalisib combination therapy in relapsed or treatment-resistant CLL better...

Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen ( Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )

ASH 2015: New targeted therapies for haematological malignancies

Dr Robert Hromas - University of Florida, Gainesville, USA

ASH 2015: New targeted therapies for haematological malignancies ( Dr Robert Hromas - University of Florida, Gainesville, USA )

Using epigenetics to manipulate cancer cells

Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA

Using epigenetics to manipulate cancer cells ( Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA )

Overcoming the barriers of the P53 dysfunction to cure blood cancers

Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA

Overcoming the barriers of the P53 dysfunction to cure blood cancers ( Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA )

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia...

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )

Combination therapy with idelalisib better prevents disease progression in...

Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA

Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen ( Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )

Study underscores promise of targeted therapies as first-line approach for...

Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )

First targeted therapy for multiple myeloma effective against hard-to-treat...

Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle...

First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle, Denmark )

More from ecancer